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Abstract Introduction In patients with venous thromboembolism (VTE), direct oral antico-
agulants (DOACs) such as edoxaban, apixaban, dabigatran, and rivaroxaban are more
convenient, safer, and just as effective as vitamin K antagonists (VKAs). Limited
information is known about the effects of patient characteristics on VTE efficacy
and safety of DOACs compared with VKAs, without appropriate effect modifier
adjustment comparisons of DOACs may be biased. This study considers the effect of
variables that can modify the efficacy and safety of edoxaban and warfarin, using
patient-level data.
Materials and Methods The primary efficacy and safety outcomes in the HOKUSAI-
VTE study were VTE recurrence and clinically relevant bleeding, respectively. Potential
effect modifiers were age, creatinine clearance, and weight. The relationship between
the percentage of time in international normalized ratio (INR) control and outcomes
were considered for the warfarin arm. Univariate and multivariate regression were
performed for each patient characteristic.
Results The relationship between treatment and VTE recurrence differed by age
(interaction p¼ 0.007) and by creatinine clearance (p¼ 0.05). VTE recurrence differed
by age for patients in the warfarin arm but not for those in the edoxaban arm and
differed by INR control in the warfarin arm (p< 0.005). A stronger relationship between
creatinine clearance and clinically relevant bleeding was found in the warfarin arm than
in the edoxaban arm (p¼ 0.04). Clinically relevant bleeding differed by the percentage
of time in INR control in the warfarin arm (p< 0.005). Age appeared to be a more
important effect modifier than creatinine clearance in patients with VTE.
Discussion The finding that efficacy in older patients was greater for those taking
edoxaban than for those taking warfarin in the HOKUSAI-VTE study needs further
investigation. Modification of the treatment effect by age for those taking warfarin
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Venous thromboembolism (VTE) is a major cause of morbid-
ity and mortality. In Europe, the estimated incidence rate of
VTE is approximately 130 per 100,000 patient-years, and
therefore between 600,000 to over 1 million VTE events or
deaths occur annually.1,2 Early diagnosis and treatment often
lead to recovery, but VTE recurrences and long-term com-
plications, such as postthrombotic syndrome and chronic
thromboembolic pulmonary hypertension, may occur.
For over 60 years, the cornerstone of treatment for VTE has
been vitamin K antagonists (VKAs) such as warfarin. Treat-
mentmaybe for short periods (3months) or for longer periods
(6months to long term) to prevent VTE recurrences. However,
VKAs decrease the clotting tendency of blood, and their effect
must be monitored carefully with frequent blood tests and
dose adaptations. Underdosing leads to increased risk of blood
clots and excessive dosing to increased risk of bleeding.
Previous studies have shown that the risks of VTE and
pulmonary embolism (PE) are four to six times higher in
patients over 70 years old than in younger patients.3 In
addition, age has been found to increase the risk of bleeding
related to anticoagulant use. The relationship between renal
clearance and age is well known, with renal clearance
reduced in proportion to increasing age.
In the past 5 to 10 years, new direct oral anticoagulants
(DOACs), such as apixaban, dabigatran, edoxaban, and rivar-
oxaban, have been demonstrated to be more convenient and
have a better safety profile than VKAs, with a proven
effectiveness at preventing VTE recurrence and long-term
complications.4–7
Many patients and clinicians prefer a once-daily treat-
ment regimen, which leads to a choice between two DOACs,
rivaroxaban and edoxaban; however, no head-to-head, ran-
domized controlled trial data are available.
The efficacy and safety of rivaroxaban versus VKAs has
been investigated in the EINSTEIN studies, addressing deep
vein thrombosis (DVT) and PE separately.5,6 The efficacy and
safety of edoxaban versus warfarin has been investigated in
one study, theHOKUSAI-VTE study,which included bothDVT
and PE patients.8 These studies revealed no notable differ-
ences in the overall results for both drugs; both studies
showed similar efficacy and improved safety of rivaroxaban
and edoxaban compared with VKA. However, the trials
differed in terms of both their populations and design.
Differences in study designsmay be of particular importance
in the presence of potential effect modifiers, such as age,
creatinine clearance, and weight. Additionally, the level of
control in the warfarin arm of the studies differed.
Previous meta-analysis has suggested increased efficacy
of DOACs compared with VKAs in patients with low creati-
nine clearance compared with patients with high creatinine
clearance, based on published aggregate data for subgroups.3
This study aimed to estimate the impact on treatment
outcomes of possible effect modifiers in patients with VTE,
using patient-level data from the HOKUSAI-VTE study.When
treatments are directly compared in real-world studies,
patient characteristics that impact outcomes may differ
between treatment arms. To ensure unbiased comparative
efficacy and safety estimates, researchers need to be aware of
these characteristics and use approaches that can adjust and
minimize differences in effect modifiers between the treat-
ment arms. For cases where there is an absence of head-to-
head trials, indirect comparisons or network meta-analyses,
which rely on the assumptions of homogeneity of study
designs and trial populations, are often performed. However,
in the presence of effect modification by patient character-
istics or study design differences, especially in treatment
patterns for the common comparator, the conclusions of
networkmeta-analysis can be biased. Sophisticatedmethods
are now available to generate indirect comparisons that can
bemade across different studieswhere patient-level data are
available from one study and aggregate data are available
from another study.9 These approaches allow for the studies
to be matched to adjust for differences in study design and
effect modifiers. Per the Decision Support Unit guidelines of
the United Kingdom’s National Institute for Health and
Clinical Excellence,10 it is important to adjust for all variables
that modify treatment effect of the new medications or the
common comparator. Further, for comparisons of studies
where effect modifiers differ between treatment arms,
approaches such as propensity score weights are possible
to adjust for the effect modifiers.
Materials and Methods
Study Populations
The efficacy and safety of edoxaban versus VKA were inves-
tigated in the HOKUSAI-VTE study that included 4,921 DVT
and 3,319 PE patients enrolled at 439 centers in 37 countries
between January 2010 and October 2012.8 Randomization
was performed with the use of an interactive Web-based
system, with stratification according to the qualifying diag-
nosis (DVT or PE), presence or absence of temporary risk
factors, and the dose of edoxaban. The HOKUSAI-VTE study
was a randomized, double-blind study that compared hepa-
rin followed by edoxaban with heparin followed by warfarin
in patients objectively diagnosed with acute symptomatic
DVT involving the popliteal, femoral, or iliac veins or with
acute, symptomatic PE with or without DVT.8 Patients
received the study drug for 3 to 12 months; the duration
was determined by the treating physician and based on the
patient’s clinical features. The primary efficacy outcome was
recurrent symptomatic VTE, and the principal safety out-
come was major or clinically relevant nonmajor bleeding.
Reported analysis of pooled data for both DVT and PE
patients found a nonsignificant lower proportion of recur-
rent VTE (3.2% vs. 3.5%) for patients receiving edoxaban than
for patients receiving warfarin. Significantly lower, clinically
relevant bleedings (8.5% vs. 10.3%) were found in the edox-
aban arm than in the warfarin arm. In this study, patient-
level data for the modified intention-to-treat population (all
randomized subjects who received at least one dose of the
study drug) from the HOKUSAI-VTE study were analyzed for
effect modifiers based on patient characteristics or study
design.
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Effect Modifiers
Patient-level data from the HOKUSAI-VTE study (edoxaban vs.
warfarin) were analyzed to identify patient characteristics at
baseline that may be effect modifiers. Analyses were per-
formed for the pooledDVT andPEgroups, and further analyses
were performed separately for those with PE and for those
with DVT only (i.e., those with DVT and not PE). Patient
characteristics considered to be potential effect modifiers
were age, creatinine clearance, and weight. Creatinine clear-
ance was calculated using the Cockcroft and Gault equation,
which includes patients’ age, weight, and gender. To assess the
effect of a failing kidney/poor kidney function on top of
the effect of age andweight, predictedminus observed creati-
nine clearance was calculated. Predicted minus observed
creatinine clearance was calculated as the difference between
predicted creatinine clearance from a linear regressionmodel,
which included age and weight as covariates, and observed
creatinine clearance. Study designwas considered only for the
warfarin group as time in international normalized ratio (INR)
control; within the study, the dose of warfarinwas adjusted to
maintain the INR between 2.0 and 3.0.
Statistical Methods
The distribution of age, creatinine clearance, and body weight
were considered through histograms. The relationship
between efficacy (i.e., VTE recurrence) and patient character-
istics was first addressed graphically by way of a scatterplot
picturing event rates in 5% deciles (20 groups selected to have
equal numbers of patients within each group, with sufficient
patient numbers in each group to enable meaningful compar-
isons across the age groups). The plots were generated for age,
creatinineclearance, andbodyweight. Foreachpotential effect
modifier of interest, a plot was generated for both treatment
groups together (bottom-left quadrant) as well as separately
for the edoxaban (top-right quadrant) and warfarin (bottom-
right quadrant) treatment groups. A logisticmodel alsowasfit
to each group and overlaid on the scatterplots; efficacy or
safety outcomes were included as the dependent variable in
the logistic models, and patient characteristics were included
(as continuous variables) as the predictor within the model.
The logisticmodelswere run for both treatment arms together
and for each of the treatment arms separately to alignwith the
presented scatterplots. This analysis provided an initial assess-
ment of the relationship between the potential effect modi-
fiers and the outcomes of interest overall and in each
treatment arm.
Univariate regression models also were performed to
assess the statistical significance of effect modification by
including an interaction term between treatment and each
effect modifier of interest, age, creatinine clearance, and
body weight. Predicted minus observed creatinine clearance
was also considered as an effect modifier. To assess which of
the effect modifiers was more predictive of changes in the
outcomes, we performed a multivariate analysis. All poten-
tial effect modifiers were considered in a single model along
with planned treatment duration (considered as a categori-
cal variable for 3, 6, and 12months of planned duration), and
stepwise reduction of the model was performed to assess
which effect modifiers remained significant predictors after
adjusting for other covariates and interaction terms. Cox
proportional hazards regression also was performed to con-
sider whether age, creatinine clearance, or weight were
treatment effectmodifierswhen simultaneously considering
the timing of the event (VTE recurrence and clinically rele-
vant bleeding) and appropriate censoring.
It is well known that INR control is a crucial predictor of
events in the warfarin arm; as such, any relationship be-
tween events and baseline characteristics may be indirectly
caused by a relationship between those baseline character-
istics and therapeutic time in INR control. To explore this, we
examined the correlations between the various baseline
variables and INR control through a series of regression
models, overlaid against scatterplots of the outcome variable
by deciles of the predictor variables.
Results
Demographics
The mean age was 55.7 years (standard deviation [SD], 16.3)
in the edoxaban arm and 55.9 years (SD, 16.2) in thewarfarin
arm (►Table 1). The percentage of patients with creatinine
clearance between 30 and 50mL/min, inclusive, was 6.5% in
the edoxaban arm and 6.6% in the warfarin arm. Of the
patients in the edoxaban arm, 12.7% had a weight  60 kg
compared with 12.6% in the warfarin arm; further, the
proportion of those with high weight (> 100 kg) was similar
between the two arms: 14.8% (edoxaban) and 15.9% (warfa-
rin). Among patients receiving warfarin, the INR was in the
therapeutic range for 63.5% of the time, above 3.0 for 17.6% of
the time, and below2.0 for 18.9% of the time. The distribution
of the effect modifiers in all patients is shown in ►Figs. 1–3.
Exploring Possible Effect Modifiers
The effect of age on VTE recurrence is illustrated in ►Fig. 1.
As expected, VTE recurrencewas found to differ according to
age (overall p¼ 0.01 from logistic regression), with higher
event rates observed as age increased from baseline. How-
ever, when only those patients on edoxabanwas considered,
VTE recurrence did not differ with age (p¼ 0.915); whereas
for the subset of patients taking warfarin, recurrence in-
creased with age (p< 0.005).
Age had almost no effect on VTE recurrence in the
edoxaban arm, but VTE recurrence increasedwith increasing
age in the warfarin arm (►Fig. 1; ►Supplementary Fig. S1).
The estimates of the univariate logistic regressions for inter-
actions between treatment and the effect modifiers of age,
creatinine clearance, weight, and INR control (limited to the
warfarin arm) are shown in►Table 2. The effect of treatment
on VTE recurrence significantly differed by age (interaction
p¼ 0.007), with the odds of having an event increasing by
11% for every 5-year increase in age. Based on these results,
the odds of having a recurrent VTE were equal between ages
52 and 53 years. Below age 52 years, the odds were lower for
the warfarin group; above age 53 years, the odds were in
favor of edoxaban. After adjustment was made for treatment
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duration, the significant interaction between age and treat-
ment was still observed.
Based on the separate regression models as creatinine
clearance increased, VTE recurrence decreased for the warfa-
rin arm but increased for the edoxaban arm (►Fig. 2). In line
with the separate regression models, a statistically significant
interaction was observed between treatment and creatinine
clearance, with VTE recurrence in the univariate analysis
(p¼ 0.047; ►Table 2; ►Supplementary Fig. S2). When the
difference between predicted creatinine clearance based on
Fig. 1 The distribution of age and the relationship between VTE recurrence and age, by treatment arm. VTE, venous thromboembolism. Note:
The top-left quadrant in this figure shows the age distribution, the bottom-left quadrant shows the relationship between the incidence of
recurrent VTE and age in all patients, and the two graphs on the right-hand side show recurrent VTE according to treatment.
Table 1 Selected baseline characteristics in HOKUSAI-VTE studya













Age, mean (SD), y 55.7 (16.3) 55.9 (16.2) 54.7 (16.0) 54.9 (15.9) 57.1 (16.6) 57.4 (16.5)
Age  75 y, n (%) 560 (13.6) 544 (13.2) 282 (11.4) 273 (11.1) 278 (16.8) 271 (16.2)
Creatinine clearance:
30–50 mL/min, n (%)
268 (6.5) 273 (6.6) 152 (6.2) 153 (6.2) 116 (7.0) 120 (7.2)
Weight, n (%)
< 60 kg 524 (12.7) 519 (12.6) 320 (13.0) 304 (12.4) 204 (12.4) 215 (12.9)
> 100 kg 611 (14.8) 654 (15.9) 360 (14.6) 379 (15.5) 251 (15.2) 275 (16.5)
Percentage of time: — — —
In INR control 63.62 62.63 65.11
INR above 3.0 16.54 17.09 15.70
INR below 2.0 19.84 20.27 19.19
Abbreviations: DVT, deep vein thrombosis; INR, international normalized ratio; PE, pulmonary embolism; SD, standard deviation.
aResults are based on the modified intention to treat population.
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Fig. 2 The distribution of creatinine clearance and the relationship between VTE recurrence and creatinine clearance, overall and by treatment
arm. VTE, venous thromboembolism.
Fig. 3 The distribution of body weight and the relationship between VTE recurrence and body weight, overall and by treatment arm. VTE,
venous thromboembolism.
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age andweight and observed creatinine clearancewas consid-
ered, no significant interaction with treatment was observed
(p¼ 0.93).
No significant interaction was found between weight and
treatment on VTE recurrence (p¼ 0.33; ►Table 2; ►Fig. 3),
and no statistically significant relationship was observed
between weight and VTE recurrence in either the edoxaban
or the warfarin arm (p¼ 0.25 and p¼ 0.80, respectively). A
decrease in VTE eventswas seen for patientswho spentmore
time in INR control (p¼ 0.001; the coefficient from the
logistic regression model was –0.013).
In the multivariate model with VTE recurrence as the
dependent variable which considered the variables weight,
duration of treatment, age, INR control, creatinine clearance
(uncorrected), and interaction terms, only the interaction
between treatment and age remained significant within the
model following stepwise reduction. Similarly, in a model
initially considering predicted minus observed creatinine
clearance following stepwise reduction, the interaction be-
tween age and treatment remained the only significant
interaction term in the model.
Analysis considering DVT and PE patients separately is
reported in the ►Supplementary Material. The interaction
between age and treatment was seen in the DVT group only;
VTE recurrencewas higher with increasing age in thewarfarin
group than in the edoxaban group, and the INR relationship
was most pronounced in the PE group (►Supplementary
Tables S1 and S2). The results of the Cox proportional hazards
models were in alignment with the findings from the logistic
regression models (►Supplementary Table S3).
Table 2 Univariate analysis of efficacy and safety event rates
VTE recurrence Clinically relevant bleeding
Age Estimate Standard error Pr(>|z|) Estimate Standard error Pr(>|z|)
(Intercept) –3.391 0.316 < 0.005 –3.040 0.212 < 0.005
Age –0.001 0.005 0.915 0.012 0.004 0.001
Treatment –1.106 0.467 0.018 0.013 0.291 0.965
Age treatment 0.021 0.008 0.007 0.003 0.005 0.486
Predicted minus observed
creatinine clearancea
Estimate Standard error Pr(>|z|) Estimate Standard error Pr(>|z|)
(Intercept) –3.424 0.092 < 0.005 –2.383 0.058 < 0.005
Predicted minus observed
creatinine clearance
0.000 0.004 0.996 –0.005 0.002 0.018
Treatment 0.144 0.126 0.251 0.209 0.078 0.008
Predicted minus observed creatinine
clearance treatment
0.000 0.005 0.993 0.006 0.003 0.074
Creatinine clearanceb Estimate Standard error Pr(>|z|) Estimate Standard error Pr(>|z|)
(Intercept) –3.563 0.255 < 0.005 –2.305 0.160 < 0.005
Creatinine clearance 0.001 0.002 0.560 –0.001 0.001 0.649
Treatment 0.792 0.351 0.024 0.627 0.219 0.004
Creatinine clearance treatment –0.006 0.003 0.047 –0.004 0.002 0.036
Weight Estimate Standard error Pr(>|z|) Estimate Standard error Pr(>|z|)
(Intercept) –3.844 0.380 < 0.005 –2.457 0.241 < 2e-16
Weight 0.005 0.004 0.247 0.001 0.003 0.741
Treatment 0.609 0.521 0.243 0.633 0.326 0.053
Treatment weight –0.006 0.006 0.333 –0.005 0.004 0.186
INR control Estimate Standard error Pr(>|z|) Estimate Standard error Pr(>|z|)
(Intercept) –2.602 0.262 < 0.005 –1.497 0.161 < 0.005
% of time in INR control –0.013 0.004 < 0.005 –0.012 0.003 < 0.005
Abbreviations: INR, international normalized ratio; VTE, venous thromboembolism.
Note: Edoxaban is the reference group in the models, and warfarin is coded as 1.
aPredicted minus observed creatinine clearance was calculated as the difference between predicted creatinine clearance from a linear regression
model, with creatinine clearance as the dependent variable and age and weight as covariates, and observed creatinine clearance. Predicted minus
observed creatinine clearance is a marker of the effect of a failing kidney/poor kidney function on top of the effect of age and weight.
bThe variable creatinine clearance is based on the Cockcroft and Gault equation, which includes patients age, weight and gender. By using the
coefficients from the model, it is possible to estimate the impact of age on VTE recurrence in patients in the warfarin arm and patients in the
edoxaban arm. For those in the edoxaban arm, a 5-year increase in age is associated with an increase in the odds of having an event by: (include
calc)¼ 11%. The odds of having a recurrent VTE for edoxaban is below that of warfarin for patients above the age of 53: exp (–3.391þ 53 –
0.001)< exp (–3.391þ 53 –0.001þ 1 –1.106þ 53 0.021). For patients below the age of 52 years, the odds are lower for the warfarin group
than for the edoxaban group: exp (–3.391þ 52 –0.001)< exp (–3.391þ 52 –0.001þ 1 –1.106þ 52 0.021).
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As age increased, therewas an increase in clinically relevant
bleeding, and this relationship appeared similar across both
arms (►Fig. 4). For safety, the relationship between creatinine
clearance and clinically relevant bleeds differed by treatment
arm (►Table 2; ►Fig. 5). For warfarin, a decrease in clinically
relevant bleeding was observed as creatinine clearance
increased; a weaker negative relationship was observed in
the edoxabanarm,but this didnot reach significance. Although
a statistically significant interaction between treatment
and creatinine clearance on clinically relevant bleeding
was observed when considering VTE and PE combined
(►Supplementary Fig. S3), it was not observed when consid-
ering VTE or PE separately (►Supplementary Tables S1 and
S2). There did not appear to be a clear relationship between
weight and the number of bleeds in patients in either the
edoxaban arm or the warfarin arm (►Table 2; ►Fig. 6). A
significant relationship was found between INR control and
bleeding events for patients taking warfarin, with decreased
clinically relevant bleeding observed as percentage of time in
INR control increased (►Table 2).
As seen in ►Fig. 7, creatinine clearance was strongly
correlated with age, with creatinine clearance decreasing as
age increased. The upper left-hand quadrant of ►Fig. 7 shows
the average creatinine clearance of 20 equally sized age groups
and indicates a strong relationship between age and creatinine
clearance. The lower-left plane of►Fig. 7 indicates a significant
positive relationshipbetweenageandpercentageof time in INR
control,which suggests that thenegative relationshipsbetween
age and events are not linked through INR control. Contrarily, a
nonsignificant positive relationshipwas found between creati-
nine clearance and INR control. Additionally, therewas a strong
relationship between weight and time in INR control.
Discussion
We analyzed the effects of a selection of risk factors, using
patient-level data from the HOKUSAI-VTE study.7 It was
assumedapriori that themost important variables to consider
wouldbeage, creatinine clearance, andweight, togetherwith a
distinction between patients whowere to be on treatment for
3, 6, or 12 months. Analysis showed a clear increase in VTE
recurrence ratewith respect to age in thewarfarinpatients but
no such effect in the edoxaban patients. Assuming a linear
relationship in the log-odds, it is estimated that the cutoff
point at which treatment with edoxaban becomes more
effective than warfarin is approximately 52 years of age. A
similar relationship was seen in a pooled analysis of the RE-
COVER studies, with the efficacy of dabigatran comparedwith
warfarin being higher in older patients and lower in younger
patients,11 although this did not reach statistical significance,
and no relationship was reported in published subgroup
analysis of the same studies.3 Based on a published subgroup
analysis of patients older andyounger than 75 years of age, the
EINSTEIN studies also reported a relationship between events
and age in the usual-care arm, although the EINSTEIN results
seem less pronounced than that which may be expected.5,12
Fig. 4 The relationship between clinically relevant bleeding and age, overall and by treatment arm.
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Fig. 5 The relationship between clinically relevant bleeding and creatinine clearance, overall and by treatment arm.
Fig. 6 The relationship between clinically relevant bleeding and body weight, overall and by treatment arm.
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A similar effect on treatment outcomes in theHOKUSAI-VTE
trial was found with respect to creatinine clearance, but
creatinine clearance is strongly related to age. Due to this
interrelation (collinearity), it was difficult to ascertainwhether
the creatinine clearance or increasing age is associated with
edoxaban being more effective. However, in models where
creatinine clearance was considered with adjustment for age,
the relationshipbetweencreatinineandVTE recurrencedidnot
differ by treatment arm. The predictedminus observed creati-
nine clearance variable is a marker of kidney function that is
above or below that expected based on a patient’s age and
weight. Since the interaction between treatment andpredicted
minus observed creatinine clearance was not significant, it
indicates that a level of creatinine clearance that differs from
that expected based on a patient’s age and weight does not
modify the effect of a treatment’s efficacy and safety. Further,
the multivariate analysis suggested that age was a stronger
modifier than creatinine clearance on treatment efficacy and
safety. This resultmaysuggest that if themodifyingeffectofage
on treatment efficacy and safety is considered in patients with
VTE, it is not necessary to consider creatinineclearance.While a
relationship betweenweight and events was assessed, no such
significant relationshipwasobserved intheHOKUSAI-VTEtrial.
Age may be considered as a surrogate marker for several
other factors that may influence the treatment efficacy and
bleeding risk. In addition to the relationship between age and
creatinine clearance, concomitant conditions and the type of
venous diseasemay be anticipated to differ between older and
younger patients. The relationship between age and other risk
factors for VTE may be complex; for example, while aging and
postmenopausal status have been found to enhance the risk of
chemotherapy-induced VTE inwomenwith breast cancer, the
rateofcancerdiagnosis inthefirst yearafterVTEonsethasbeen
found to be lower in the elderly compared with younger
Fig. 7 relationship between age, INR control, and creatinine clearance. INR, international normalized ratio.
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patients.13Thenumberof factorswithwhichage is relatedmay
be one explanation for age being a stronger treatment effect
modifier than creatinine clearance in the HOKUSAI-VTE trial.
INR control did not explain the significant interaction
found between age and treatment on efficacy in thewarfarin
arm. This outcome strengthens the relationship between
increasing age and decreasing efficacy of warfarin. Addition-
al analyses that adjusted for the planned treatment duration
did not alter this finding. While age and creatinine clearance
are strongly negatively correlated, and age and percentage of
time in INR control are positively correlated, one would
expect a significant negative relationship between creatinine
clearance and INR control.
Conclusion
Analysis showed a consistent rate of VTE recurrence with
respect to age in the edoxabanpatient,whilewarfarinpatients
had a clear increase in the HOKUSAI-VTE trial. Similarly, out-
comes differed bycreatinine clearance in thewarfarinpatients
butnot in theedoxabanpatients. Ageappeared tobea stronger
predictor of efficacy and safety than creatinine clearance,
although the two are highly correlated.
To compare DOACs based on data from different studies,
it is important to consider differences in possible effect
modifiers, including patient characteristics and study
design. This analysis of data from the HOKUSAI-VTE study
highlighted key potential effect modifiers of treatment
effect, which may have implications for both direct compar-
isons between DOACs and VKAs and indirect comparisons
between DOACs. Further research to confirm these findings
would be of benefit, it would also be of interest to investi-
gate these findings in cancer patients taking DOACs com-
pared with VKAs.
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